Spyre Therapeutics (SYRE) Invested Capital (2016 - 2025)
Historic Invested Capital for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $466.1 million.
- Spyre Therapeutics' Invested Capital rose 3237.16% to $466.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.1 million, marking a year-over-year increase of 3237.16%. This contributed to the annual value of $542.9 million for FY2024, which is 19280.82% up from last year.
- Latest data reveals that Spyre Therapeutics reported Invested Capital of $466.1 million as of Q3 2025, which was up 3237.16% from $515.7 million recorded in Q2 2025.
- Spyre Therapeutics' Invested Capital's 5-year high stood at $542.9 million during Q4 2024, with a 5-year trough of -$237.9 million in Q3 2023.
- In the last 5 years, Spyre Therapeutics' Invested Capital had a median value of $119.0 million in 2021 and averaged $187.6 million.
- In the last 5 years, Spyre Therapeutics' Invested Capital crashed by 45214.57% in 2023 and then surged by 97706.75% in 2024.
- Quarter analysis of 5 years shows Spyre Therapeutics' Invested Capital stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then soared by 268.56% to $185.4 million in 2023, then surged by 192.81% to $542.9 million in 2024, then fell by 14.14% to $466.1 million in 2025.
- Its Invested Capital was $466.1 million in Q3 2025, compared to $515.7 million in Q2 2025 and $525.4 million in Q1 2025.